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Background
Heart failure (HF) with preserved ejection fraction (HFpEF) is common and increasing in prevalence. 1 HFpEF occurs in association with advanced age and cardiovascular, metabolic and pro-inflammatory comorbidities. 2, 3 At the integrative level, patients with HFpEF display impaired left ventricular (LV) relaxation and increased diastolic LV stiffness. 4, 5 While arterial and LV systolic elastance (stiffness) are increased in HFpEF, resting contractile function is subtly impaired, as is the ability to enhance arterial, chronotropic and LV systolic and diastolic performance with exercise (impaired reserve function). [5] [6] [7] [8] Chronic elevation of LV filling pressures leads to left atrial remodeling and dysfunction, mixed pulmonary hypertension and ultimately, right ventricular (RV) remodeling and dysfunction. 5, 9 Increased LV stiffness suggests passive myocardial stiffening due to fibrosis and/or altered cardiomyocyte function. 6, 10 However, the underlying myocardial alterations in HFpEF are incompletely defined as endomyocardial biopsy and surgical specimens commonly available in HF with reduced EF (HFrEF), are rarely available in HFpEF. A small number of studies obtained endomyocardial biopsies in highly selected, younger HFpEF patients and reported myocyte hypertrophy, interstitial fibrosis, incomplete myocardial relaxation and increased cardiomyocyte stiffness, as well as evidence of systemic and myocardial inflammation and oxidative stress. [11] [12] [13] [14] [15] [16] [17] Based on these elegant studies, a new paradigm for the pathophysiology of HFpEF has been proposed wherein comorbidities lead to a systemic pro-inflammatory state and coronary microvascular endothelial inflammation, impairment in endothelial-cardiomyocyte nitric oxide signaling, inflammatory cell infiltration and production of pro-fibrotic cytokines resulting in diastolic dysfunction due to altered cardiomyocyte function and extracellular matrix. 3 emodeling and dysfunction, mixed pulmonary hypertension and ultimately, right ht t v v ven en e tr tr tric ic icul ul ular ar a RV) remodeling and dysfunction. 5, 9 I I Inc nc cre re r a a ased d d L L LV V stiffness suggests passive m m myo ocardial stiffeni ni n ng g d d due ue ue to fibrosis and/or al lte ere red cardiomy my yoc cyt yte e e fu fu unc nc ncti ti ion on on. . 6, 6, 10 10 H How ow oweve e er, the u un nde e erl rl lyi ying n ng m myo y yoca car rdi di dial l a alt lt ter er rat atio io ons ns ns i i in n HF HF HFpE E pEF F F ar re e e in in nco co c mp mp mple le lete tely ly y d d def efin in ned ed d a as e en endo do domy my myoc oc car ar rdi di dial al al b b bio io iop p psy sy y an nd nd s s su ur urgi gi ica ca c l l l sp sp pec ec e im im me en ens s co co comm mm mmo on only ly y a a ava vail il lab b ble l n HF with red ed duc uc u ed ed ed E E EF F F (H (H ( Fr Fr F EF EF E ), ), ), a a are re e rar ar arel el ly y y av av avai ai aila la abl bl b e e e in in H H HFp Fp FpEF EF EF. . . A A A sm sm smal al all l nu nu numb mb mber er er o o of f f st st s udies Microvascular endothelial inflammation is also associated with endothelial dysfunction and microvascular rarefaction. 18 The resultant reduction in coronary microvascular density (MVD) may impair oxygen delivery with stress, limiting LV systolic and diastolic reserve function. 19, 20 However, studies in human HFpEF myocardium are limited and MVD in particular has not been assessed in HFpEF.
We hypothesized that cardiac hypertrophy, microvascular rarefaction and myocardial fibrosis are common and related in patients with HFpEF. To test this hypothesis, we obtained transmural LV specimens from patients who had undergone postmortem examination with an ante mortem diagnosis of HFpEF and age-appropriate control patients. Whole field digital microscopy and automated digital histopathologic analyses were used to quantify fibrosis and MVD while hypertrophy was assessed by age-, sex-, and body size-adjusted cardiac weight and histological characterization (by cardiovascular pathologists). Severity of epicardial coronary artery disease (CAD) was assessed by serial coronary artery sectioning and gross and histologic evaluation was performed by a pathologist.
Methods
This study was approved by the Mayo Clinic institutional review board and the Mayo Clinic biospecimens subcommittee.
Study subjects
Consecutive adult subjects with a prior HF hospitalization (primary dismissal diagnosis of HF MVD while hypertrophy was assessed by age-, sex-, and body size-adjusted cardiac weight and hi ist st tol ol olog og ogic ic ical al al c cha h ra ra rac ct cte erization (by cardiovascular pa pa p t th hologists). Sev v ver e it ty y y o of of epicardial coronary f ar rte e ery ry disease ( (CA CA CAD) D) ) w wa as as a a as ss sse es esse sed d d by by b se e erial l l c co orona na nary a a ar rt rter ery y y se sect ct tio io oni ning ng g a an nd d gr gr ros oss s an an nd d d hi h h st st st l ol olog og ogic ev val al alua ua uati ti t on on w w was as p p per r rfo for rm me ed ed by y y a pa pa path th thol olo og ogis is ist t. t.
an LVEF 40% within a median of 1 day of the HF event were identified. Subjects with more than mild aortic or mitral stenosis, infiltrative or hypertrophic cardiomyopathy, complex congenital heart disease or heart transplant recipients were excluded from the study. To assess the relative severity of microvascular rarefaction and fibrosis in HFpEF as compared to HFrEF using the technologies employed in this study, we also identified a subgroup of HFrEF patients (EF < 40% at HF diagnosis, n=27) who underwent autopsy using similar methods as above.
Data abstraction
Clinical and pathology characteristics were manually abstracted from the medical records and autopsy reports. Comorbidities were defined as described previously, 2 and as outlined in Supplemental methods.
Autopsy and tissue processing
Autopsies were conducted according to the Mayo institutional guidelines and standardized protocols as described previously. 21 Semi-quantitative assessment of gross remodeling (ventricular and atrial sizes, presence of hypertrophy, fibrosis or infarction) was defined by the performing pathologist. Absolute heart weight was reported, as well as the percentage of expected heart weight, derived from established age nomograms based on sex, body weight and
To assess the relative severity of microvascular rarefaction and fibrosis i in n n HF HF H pE pE pEF F F as as as compared to HFrEF using the technologies employed in this study, we also identified a subgroup of f H H HFr Fr FrEF EF EF p p pat at atie i nt nt ts s s (E (EF < 40% at HF diagnosis, n= n= n=2 27 7) who underw w went t au au aut to topsy using similar body height. 21 The epicardial coronary arteries were sectioned serially and atherosclerosis was graded as 0-4 with grade 0 indicating no stenosis and grade 4 indicating 75% luminal area stenosis (analogous to 50% angiographic diameter stenosis).
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After gross examination, hearts were serially sectioned along the short axis at apical and mid-ventricular levels. From the mid-ventricle, representative transmural sections of the left ventricular wall and septum were procured, fixed in 10% neutral buffered formalin and embedded in paraffin for histologic analysis. For standardization, the inferior wall was the region analyzed, unless a gross infarct was seen. Alternately, an adjacent non-infarcted portion of the wall was chosen in the following order of availability: inferolateral, lateral, anterolateral, anterior, anteroseptal or inferoseptal.
Histochemistry for fibrosis detection
Sulfated Alcian blue (SAB) with van Gieson's counterstain was used to differentially stain amyloid (green) and collagen (red). Four m-thick paraffin embedded LV sections were deparaffinized in xylene and rehydrated with alcohol. Sections were immersed in acetic acid, stained with SAB, hematoxylin then picric acid and finally counterstained with van Gieson's.
Histologic slides were reviewed by a cardiovascular pathologist (WDE or JJM) who was blinded to the group; those with amyloid deposition were excluded from the study.
Immunohistochemistry for coronary microvascular detection
Epitopes were retrieved from deparaffinized, rehydrated parallel tissue sections and non-specific binding was blocked. Sections were then incubated with a monoclonal mouse anti-human platelet endothelial cell adhesion molecule-1 (PECAM-1)/cluster of differentiation 31(CD31)
antibody (Dako, Carpinteria, Calif) in a 1:200 dilution. The bond was detected by a horseradish wall was chosen in the following order of availability: inferolateral, lateral, anter rol o olat at a er r ral al a , , ,
anterior, anteroseptal or inferoseptal.
Hi Hist st stoc oc che he hemi mi mist st stry y f f fo or or fibrosis detection S Su Sulf f fa ated Alcia an n bl bl b u ue ue ( ( (SA SA AB) B) B) w w wi it ith h va va van n G Gi Gie eson n n's s co ou un n nter r rst st tai ain n n w wa was s u us sed ed t t to o di diff ff ffer er ren enti ti tial al ally ly ly s s sta a ain in in am m myl yl yloi oi oid d (g (g (gre re reen en) ) an n nd d c co coll ll lag agen n n ( (re re red) d) d). . Fo Fo our ur r m-m m-th th thic ick k pa pa p r ra r ff ff ffin in in e emb mb m ed ed edde de ded d LV V V s sec ec e ti ti t on on ns s we we wer re re deparaffinized ed d i i in n n xy xy xyle lene ne ne and nd nd r r reh h hyd yd y ra ra rate ted d d wi wi w th th th a a al l lco co oho ho hol. l. l S Sec ec e ti ti tion on ons s s we w w re re re i i imm mm mmer er erse sed d d in in in a a ace ce ceti t c acid, peroxidase linked secondary antibody conjugate kit (Leica Biosystems, Newcastle Upon Tyne, UK), and visualized using 3,3'diaminobenzidine tetrahydrochloric acid chromogen. Tissue sections were counterstained with hematoxylin for visualization of the nuclei.
Digital image acquisition and processing
Digital images were captured at 20X magnification with a resolution of 1.3 megapixels and scanned into Baccus/NDPI format using NanoZoomer Digital Pathology whole field microscopy (Hamamatsu photonics K.K; Hamamatsu city, Japan).
Quantitative fibrosis image analysis
Images were processed using an automated custom designed quantitative analysis software Images were loaded into the software in Baccus native file format, down-sampled to 2.5% and a Gaussian blur with a kernel size of 7x7 was applied. Tissue was segmented from the glass slide using an automated and adaptive threshold. The automatic threshold algorithm utilized a combination of intensity histogram-based methods and a homogeneity measurement to calculate a threshold that divides the selected set of pixels into two subsets to maximize heterogeneity. The generated classification mask of the tissue region was then overlaid onto a 5x copy of the image.
The auto-adaptive threshold was then applied in a 2-stage approach. Im Imag ag ages es w w wer er re e lo lo oad ad ded ed i i int nt n o o o th th the e e so so oft ftwa wa war re re i i in n n B B Bac ac ccu u us na na nat ti tive ve e f fi il ile e fo fo form rm ma at at, , do do dow wn wn-s -s sam am amp pl pled d d t to o o 2.5% and a G Gau au auss ss sia ia ian n n bl bl b ur u u w w wit it ith h a a a ke ke k rn rn r el el l s siz iz ize e e of of of 7 7x7 x7 x7 w w was as a a app pp ppli li lied ed ed. . . Ti Ti iss ss s ue ue ue w w was as as s seg eg egme me ment nt nted e from the e f f threshold was then calculated using the remaining set of pixels in the tissue, segmenting the SAB stain. Fibrosis was quantified as a percent of the total tissue area.
Quantitative coronary MVD image analysis
An automated quantitative analysis bright-field vessel detection and classification algorithm (Definiens Tissue Studio 3.5; Definiens®, München, Germany) was applied to PECAM-1 stained slides. The process consisted of 3 main steps: (1) manual region of interest selection (2) vessel detection (PECAM-1; CD31 stain) and ( A modifiable threshold algorithm was used for vessel detection. To maximize discrimination between brown stain and background stain, the stain values of the brown chromogen were based on conversion of the Red, Blue, and Green (RBG) space to the HueSaturation-Density (HSD) model which has been shown to be superior. 23 To exclude nonspecific binding, stain fragments and artifacts, a stain intensity threshold of 0.225 and a minimum stain area of 10 μm 2 were set. This minimum stain area was selected based on pilot measurements of the area of the smallest vessels. Sides were analyzed in tiles at 10X magnification. Sensitivity analysis was performed quantifying total vessel density with and without a minimum stain area restriction (Supplemental methods and results).
Microvessels were defined as the combination of capillaries (endothelial monolayer and area between 10 μm 2 and 78.5 μm 2 ; average luminal diameter 10 μm) 24, 25 and small precapillary arterioles (area 78.5-314 μm 2 ; average luminal diameter 10 to 20 μm). 
Echocardiograms
Transthoracic echocardiograms closest to the date of HF diagnosis were obtained. LV EF was available on all HF subjects, however availability of other echocardiographic parameters was
inconsistent. An LVEF 40% was used as a cut off for definition of HFpEF. Sensitivity analyses excluding HFpEF patients with EF 40-49% at diagnoses were performed. For assessment of correlation of echocardiographic parameters with histology, the last echocardiographic variable obtained closest to death was used.
Electrocardiograms (ECGs)
ECGs closest to death were interpreted and voltages were measured manually blinded to the group (n= 224). LVH was determined by voltage criteria (Cornell and Sokolow). 
Statistical Analysis
Echocardiograms
Transthoracic echocardiograms closest to the date of HF diagnosis were obtained. LV EF was av vai ai aila la labl bl ble e on on on a a all H H HF F F subjects, however availabilit t ty y y o of other echocar ar ardiog og gra ra raph p ic parameters was n nco o ons n istent. An An L LVE VEF F 40 40 40% % % w wa was s us us used ed d a a as a cu cu ut of f ff f for d de efi fin ni n ti ti t on on n o of f HF HF HFpE E EF. F. . S S Sen ensi si siti ti ivi vi vity ty y a a an na naly ly l s s ses ex xcl cl clud ud udin in i g g g HF HF HFpE pEF F pa pa p ti ti ien n nts ts w wit it i h h h EF EF EF 4 4 40-0--49 49 9% % % at t t di di d a ag agn n nos s ses s s w we were re e p pe er erfo fo form rm rmed ed d. Fo Fo For r as as a se se ses ss ssm me men nt nt o of f f correlation of of f e e ech ch c oc oc ocar ar ardi di diog ogra ra raph ph p ic ic c p p par ar aram am met et eter er ers s s wi wi with th h h h his is sto t lo lo logy gy gy, , , th th he e e la la l st st st e e ech ch choc oc ocar ar ardi di iog og ogra ra raph ph phic i variable variables as appropriate. We used least squares linear regressions to compare fibrosis and MVD between groups (HFpEF and control) adjusting for pertinent covariates. Variables which were not normally distributed were log transformed for statistical analysis. All analyses were 2 tailed and a p value <0.05 indicated statistically significant differences.
Results
Clinical characteristics
The study included 228 subjects ( . There were no significant differences in age or sex distribution between the groups ( Table 1) . HFpEF subjects had more cardiovascular comorbidities (hypertension, diabetes mellitus (and CAD), conduction system disease and ECG evidence of LV hypertrophy ( Table 1) .
Clinical characteristics of HFpEF subjects in this series were generally comparable to observational studies (Supplemental Table 1 ). The immediate cause of death as defined by the autopsy report differed by group with more HFpEF patients dying of HF and other cardiovascular causes (Supplemental Table 2 ).
Autopsy Findings
As compared to controls, HFpEF patients had a higher body mass index (BMI) and body surface area (BSA) at the time of autopsy ( Table 2) .
Heart Weight
The absolute heart weight (HW) and age, sex and body size adjusted heart weight (percentage of expected HW) were higher in HFpEF than controls ( Table 2 and Figure 1 ). The distribution of HW and % expected HW were both skewed but log transformed % expected HW was normally differences in age or sex distribution between the groups ( Table 1) . HFpEF subje je ect cts s s ha ha had d d mo mo more re cardiovascular comorbidities (hypertension, diabetes mellitus (and CAD), conduction system di ise se eas as ase e e an an nd d
d EC E E G G G e ev evidence of LV hypertrophy (T Ta Tab b ble 1).
Clinica al l l ch ch char arac ac cte e eri ri rist st stic ic cs s s of of H H HFp Fp F EF EF F su ub bj jects s s i in n th hi his s s se se eri ies es w w we e ere e g ge en ne era ra al ll lly y y co co omp mp mpar arab ab ble le le t t to o were associated with HW (p>0.05 for both) ( 
Gross Pathology
Biventricular hypertrophy, biventricular and atrial dilatation, old and new infarction and macroscopic evidence of fibrosis were all more common in HFpEF patients ( Table 2) . Of HFpEF patients, 28 (23%) had no gross hypertrophy of either chamber, 35 (28%) had only LVH, 4 (3%) had only RVH, while 57 (46%) had both.
Microscopic pathology
Histologic LV cardiomyocyte hypertrophy, infarction and fibrosis were all more common in HFpEF patients ( Table 2) .
Coronary artery disease in control and HFpEF
Serial coronary artery sections showed more extensive CAD in HFpEF patients with a higher CAD total score and a greater frequency of vessels with 50% luminal diameter stenosis ( Figure   1 ). Of the 119 HFpEF patients with serial coronary sections, 77 (65%) had at least one vessel with 50% stenosis. Of patients without a clinical diagnosis of coronary disease (n=41), 13
(32%) had at least one vessel with >50% stenosis while 64 (82%) of the 78 patients with a
Gross Pathology
Biventricular hypertrophy, biventricular and atrial dilatati t t on, old and new infarction and ma macr cr cros os osco copi pi pic c e evid id de en ence of fibrosis were all more c c com om ommon in HFpEF EF E p pat at tie ie ient n s ( Table 2) . Of clinical diagnosis had at least one stenosis 50%. HFpEF patients with EF 50% at diagnosis tended to have less severe CAD at autopsy (CAD total score 12 (7-14)) than HFpEF patients with EF 40-49% at HF diagnosis (12.5 (11-15), p=0.06). The percent of patients with at least one vessel with >50% stenosis was lower in HFpEF patients with EF 50% (61%) than in those with EF 40-49% (81%, p=0.04). CAD sum score was significantly associated with age at death, sex (higher in men) and diabetes mellitus. Adjusting for these variables, CAD was more extensive in HFpEF than control ( Table 3 ).
The coronary microvasculature in control and HFpEF
In the study population as a whole, the median tissue area analyzed was 2.29 cm 2 . MVD was normally distributed. MVD was diminished in HFpEF compared with controls, both overall (27% reduction in median MVD) and within each myocardial region ( Group explained 23% of the variability in MVD ( Table 3) . Adjusting for cohort group, MVD increased slightly with increasing age at death but sex was not significantly associated with MVD. Adjusting for group and age at death, neither history of diabetes nor systemic hypertension nor severity of coronary atherosclerosis at death (as assessed by the CAD total score) were associated with MVD (Table 3) . Further, in both HFpEF patients and controls, those without or with a history of hypertension had similar MVD (Supplemental Figure 5A ).
When analysis was restricted to patients with no epicardial coronary artery stenosis >50% normally distributed. MVD was diminished in HFpEF compared with controls, b bot oth h h ov ov ver r eral al all l l 27% reduction in median MVD) and within each myocardial region ( Table 2 and Figure 2 ).
HF HFpE pE pEF F F pa pa ati ti tien en nts h h ha ad ad lower MVD than controls w w whe he h n n HFpEF patie ie ent n s wi wi wit th th an EF of 40-49% at d di diag g gno n sis (n=2 27) 7) 7) w w wer ere e e ex ex xcl cl clud ud uded e ed (c (c co on ontr r ro ol l 13 316 6 6 (114 14 148-14 14 1467 67) ) ) v ve vess ssel els/ s/mm mm m Findi ing ng ngs s s we we were re r a als l l o o si si simi mi m la la lar r r wh wh w en en en o o onl nl nly y y de de dens ns n it it i y y y of f f ca ca capi pi pill ll lar ar arie ie i s wa wa was s s as as asse se sess ssed ed ed ( ( (co co cont nt n rol 1044 Adjusting for group and age at death, the severity of hypertrophy as assessed by Log % expected heart weight) was inversely associated with MVD ( Table 3 ).
Group differences in MVD persisted when no minimal stain area was used for analysis (Supplemental results).
LV fibrosis in control and HFpEF
In the study population as a whole, % area fibrosis was skewed but log % area fibrosis was normally distributed and used for statistical comparisons. HFpEF patients had greater % area fibrosis than control ( Table 2 and Figure 3 ). Findings were similar when HFpEF patients with an EF 40-49% at diagnosis were excluded (7.1 (5.1-9.0)% control vs 9.6 (6.8-13.5)% HFpEF; p<0.0001, Cohort group explained 9 % of the variability in log % area fibrosis ( Table 3) . Adjusting for cohort group, there was no significant association between age at death, sex, history of diabetes or systemic hypertension or severity of hypertrophy (as assessed by log % expected heart weight) and log % area fibrosis (Table 3) . Further, in both HFpEF patients and controls, those without or with a history of hypertension had similar percent fibrosis (Supplemental Figure 5B) .
Adjusting for group, severity of coronary atherosclerosis at death (as assessed by the CAD total score) was not significantly associated with log % area fibrosis ( Table 3) . When analysis was restricted to patients with no epicardial coronary artery stenosis > 50% (88 control n the study population as a whole, % area fibrosis was skewed but log % area f fib ib bro o os sis s s wa wa was s s normally distributed and used for statistical comparisons. HFpEF patients had greater % area fibr br ros os osis is is t t tha ha han n n c cont nt ntro ro rol l ( Table 2 and Figure 3 ). Fin n nd di d n n ngs were simil lar a a w whe he hen n n HFpEF patients with an n E E EF F 40-49% % a at t t d d diag agno no osi si sis s s we we were re e e exc xc clu lu ud de ed ( (7 7. 7 1 1 (5.1 .1--9.0 0 0) )% )% c c co on ontr trol ol v vs s 9. 9 9 6 6 (6 (6.8 8 .8-1 -13. 3.5) 5) 5)% % % HF HF HFpE pE pEF; F; F; p< p< <0. 0. 0 00 00 0001 01, , ,
Cohor or rt t t gr gr grou ou oup p p ex ex expl p ai ai aine ne ned d 9 9 9 % % % of of f t t the he he v v var ar aria ia abi bi b li li lity ty y in n n lo lo log g g % % % ar ar area ea a f f fib ib ibro ro rosi si s s s s ( (Ta Ta Tabl bl ble e e 3 3 3). ) ) Adjusting g g and 38 HFpEF), % area fibrosis was higher in HFpEF (9.4 (6.9-12.8)%) than control (7.4 (5.6-9.0)%; p = 0.002) patients and % area fibrosis was similar in HFpEF patients with (9.5 (6.8-14.6) %) or without (9.4 (6.9-12.8) %; p=0.70) any epicardial coronary artery stenosis > 50%.
Association between fibrosis and MVD
Log % fibrosis increased with decreasing MVD in both control (r=-0.28, p=0.004) and HFpEF (r=-0.26, p=0.004). Adjusting for MVD attenuated but did not eliminate group differences in Log % fibrosis ( Figure 3B ).
Echocardiographic characteristics, MVD and myocardial fibrosis
LV mass (r=-0.29, p=0.01, n=78) and E/e' ratio (r=-0.42, p= 0.02, n=30) were each negatively associated with MVD in HFpEF (Supplemental Figure 6) . While the extent of fibrosis tended to correlate with E/e' (r=0.35, p=0.06), there was no significant association between fibrosis and LV mass (Supplemental Table 3 ).
Electrocardiographic characteristics, MVD and myocardial fibrosis
QRS duration and QTc interval were each negatively associated with MVD and positively associated with fibrosis severity (in HFpEF and control combined) (Supplemental Figure 7) .
Microvascular density and fibrosis in HFpEF versus HFrEF
The clinical and autopsy characteristics of HFpEF and HFrEF patients were similar except for more left ventricular dilatation in HFrEF, more gross but not microscopic fibrosis, and more microscopic but not gross evidence of infarction in HFrEF (Supplemental Table 4 ). On quantitative analysis, neither MVD nor fibrosis differed between HFpEF and HFrEF (Figure 4 A   and B) . In all patients, adjusting for group (dummy variables), log % fibrosis remained inversely related to MVD (Figure 4 C) . Adjusting for MVD, % fibrosis was higher in HFrEF as compared to control subjects but similar in HFpEF and HFrEF. Previous biopsy studies excluded patients with significant angiographic evidence of coronary disease and enrolled patients who were younger at HF diagnosis (mean age early 50's -60's vs 75 years here), used a combination of RV and LV biopsies, had much smaller and exclusively endocardial specimens for review, did not quantify extent of non-critical coronary disease and did not assess MVD or its association with myocardial fibrosis. Thus, the current study expands upon previous studies and provides information regarding LV structure in elderly
HFpEF patients more typical of the HF epidemic.
13, 14, 28
Hypertrophy in HFpEF
Hypertrophy was present in HFpEF as cardiac weight was higher in HFpEF patients than controls and there was gross and microscopic LV myocardial hypertrophy as well as RV hypertrophy and atrial enlargement in HFpEF. The extent to which the increase in cardiac weight was due to LV versus other chamber hypertrophy or epicardial adiposity cannot be ascertained in our study as neither chamber specific weights nor dissection of epicardial fat was performed.
Notably, the mean cardiac weight in HFpEF here (544 g) is lower than previously reported in autopsy studies of adults with idiopathic dilated cardiomyopathy (605 g), 29 aortic stenosis (780 g) 30 or hypertrophic cardiomyopathy (600-719 g) 31 but the lack of age, sex and body size adjusted values in previous studies hinder direct comparisons and heart weight was similar in
HFrEF and HFpEF patients in this autopsy series.
Imaging studies indicate that concentric LV remodeling and hypertrophy, while common, are not severe in HFpEF 32 and a recent observational study found that height indexed LV mass was increased by 35% in elderly HFpEF versus age/sex matched healthy controls. 2 Here the percentage of expected cardiac weight was 50% higher in HFpEF than controls, suggesting multi-chamber remodeling and/or epicardial adiposity contributes to the increases in cardiac controls and there was gross and microscopic LV myocardial hypertrophy as wel el ll l l as as a R R RV V V hypertrophy and atrial enlargement in HFpEF. The extent to which the increase in cardiac weigh wa was s s du du due e to to to L L LV V V ve ve er rs rsu us other chamber hypertroph h hy y y o or r epicardial ad d dip i m os sit it ity y y cannot be ascertained in our r st s udy as n nei ei ith th t e e er c cha ha h mb mb mber er er s s spe peci ci cifi fi fic c we weigh h hts s nor r r d d diss sec ec ecti tio on n o of f e ep epic icar ardi d d a a al f fa at at w was as s p per er e fo fo form m med d ed.
No No ota ta tabl bl bly, y, y, t the he he m mea ea an n ca car rd rdi ia ac c we we eig ig ght ht ht in in in H H HFp Fp FpEF EF EF h h her er e e e (5 5 544 44 4 g g g) ) ) is is is low ow owe er er t t tha ha h n n n pr pr rev ev vio io i us us u ly ly ly r r rep epo o ort te ted d i in in autopsy stud die ie es s of of f a a adu du dult lt ts s wi wi with th h idi di dio o opa pa ath thic ic ic d d dil il lat at ated ed ed c c car ar a di di d om om myo yo yopa pa path th thy y y (6 6 605 05 05 g g g), ), ), 29 29 29 a aor or orti ti tic c c st st sten en enosis (780 weight in HFpEF.
Coronary disease in HFpEF
The prevalence of coronary disease in HFpEF is poorly described with older studies using variable ascertainment methods reporting prevalence from 0-67% 33 Two recent large observational studies and a recent catheterization laboratory based study report a clinical or angiographic diagnosis of coronary disease in 50% -68% of HFpEF patients. 2, 9, 34 There is a potential for over-or under-diagnosis of coronary disease in elderly HFpEF patients. 33 Our findings are consistent with this as significant coronary atherosclerosis existed in subjects without known CAD, while among those with a clinical diagnosis of CAD, significant atherosclerosis was variably present. This may result from a bias against coronary angiography in older HF patients with normal as opposed to reduced EF and the limited sensitivity and specificity of non-invasive CAD detection in HFpEF as recently described.
34
Decreased coronary MVD in HFpEF
To our knowledge, this is the first study to examine MVD and its association with LV fibrosis in HFpEF. In the few studies that have assessed MVD in biopsies or autopsy specimens from humans with cardiovascular disease, histological and analytical methodologies and microvasculature definitions vary widely, thereby hampering comparisons of absolute values for MVD observed in HFpEF and controls to that observed in other cardiovascular diseases.
However, the overall reduction in MVD in HFpEF (27%) was similar to that observed in HFrEF patients studied here and similar to that observed in other studies in HFrEF patients where a 30%-40% reduction in mean MVD in HFrEF versus controls was observed. 35, 36 Advanced age and common HFpEF comorbidities such as obesity, systemic hypertension and diabetes mellitus have been shown to be associated with coronary microvascular atherosclerosis was variably present. This may result from a bias against coronar ry y y an an a gi gi giog og ogra ra raph ph phy y n older HF patients with normal as opposed to reduced EF and the limited sensitivity and p pec ec cif if ific ic icit it ity y y of of of non on n-i -i -inv n asive CAD detection in HF F FpE pE pEF as recently de d d sc cri ri ibe be bed.
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D Dec cr creased co oro rona na nary y M M MVD VD VD i i in n n HF HF Fp pE pEF F F
To To o o our ur ur k kno no owl wl wled edg ge ge, , , th thi i is i i is s th the e e fi fi irs rs rst t t st st stud ud dy y y to to to e e exa a ami mi m n n ne e ci irc c cu ulating pro-o-a a an nd an an nti i a -a -ang ng ngio io ioge gen ni nic c c fa fa act t tors 44 wit th h w wide de desp spr r read ad a ( (in incl clud ud din ing g co co or ro rona nar ry ry) ) ) mi mi icr cr c ov ov ovas ascu cu ula la lar r ra ra are e efa fac ct tio o on. n. 45 5, 5, 46 6 6 I I Ind nd ndiv iv ivid id dua ua als ls ls w w wit it ith h h c c car rd rdio o ova va vasc sc scul ul lar ar a r r ris sk k k fa fac c cto or ors s si si s m mi mila la ar r t t to H H HF Fp FpEF EF F r r obesity, diab abet et etes es e m m mel elli li l tu tu t s an an and d d hy hy hype pe pert rt r en en nsi si ion on on) ) ar ar are e mo mo more re r p p pro ro rone ne ne t t to o o pr p p e-e-e-ec ec ecla la amp mp mpsi si s a. a. a. R R Rem em emov ov o al of the the longitudinal vessels in the mid-wall is systematic and likely equivalent in HFpEF and control subjects. Analysis of MVD per region (sub-epicardium, mid-wall and sub-endocardium) showed consistent and proportionate reduction in HFpEF. Finally, MVD in the three regions were not significantly different, although there was an expected trend towards lower MVD in the midwall.
Fibrosis in HFpEF
Endomyocardial biopsy studies in HFpEF and variable comparator groups have demonstrated enhanced fibrosis in HFpEF compared to controls as evidenced by collagen I and III gene expression 16 or collagen volume fraction 12, 17 and similar degrees of fibrosis in HFpEF and
HFrEF, consistent with our findings. 13, 14, 28 In previous studies, the values for collagen volume fraction in HFpEF (2-13%) and comparator (2-4%) groups have varied widely, likely owing to variability in tissue procurement, histologic and analytical methods. 12-14, 17, 28 We found mean % fibrosis area of 7.5% in control and 11.2% in HFpEF (median 7.1 and 9.6% respectively). The higher fibrosis area in controls may reflect differences in histologic techniques or analytical methods, the differences in tissue procurement (autopsy) or the more advanced age of controls.
The correlation between fibrosis as assessed here and ante-mortem conduction system disease provides support for the validity of fibrosis measurement and its physiologic impact in HFpEF. 48 The extent of fibrosis was higher in HFpEF than control in subjects with or without a history of hypertension and among HFpEF patients, fibrosis was similar in those with or without hypertension. These findings suggest that comorbidities other than hypertension perpetuate fibrosis. While significant, the difference in fibrosis between HFpEF and controls was modest and the difference in fibrosis between HFpEF and HFrEF patients was not significant suggesting that mechanisms other than fibrosis contribute to diastolic and systolic dysfunction in HF. 12, 14 HFrEF, consistent with our findings. 13, 14, 28 In previous studies, the values for co co oll llag a a en en n v v vol ol olum um u e fraction in HFpEF (2-13%) and comparator (2-4%) groups have varied widely, likely owing to va ari ri iab ab abil il ilit it ity y y in in in tissu su sue e e procurement, histologic and d a a ana na alytical method od ds. 12-2-1 14, 14, 17 1 , 28 We found mean % fi fi ibr r ros o is area of of 7 7 7.5 5 5% % % in in i c c con on ontr tr trol o ol a an nd nd 1 11 1.2 2 2% i in n H HFp p pE E EF ( ( (m me medi di ian n n 7 7. .1 and nd d 9 9.6 6% % % r re esp spec ec ecti ti tive vely y). ) ). T T The he e hi high gh gher er er f fib ibro ro osi si sis s ar ar rea a a i in n co co ont ntro o ols ls l ma ma may y y re refl fl f ec ec ect t t d d diff ff ffer er e e en enc ce c s s s in in n h h hi i ist t tol ol o og og gic ic c t t tec ec chn n niq iqu ue ues s s or or r a a an n naly ly lyti i ica cal l methods, the e d d dif if ffe fe ere re renc nc nces es s in n n ti ti iss s s ue ue ue p pro ro rocu cu ure re reme me ment nt n ( ( (au au aut t top op opsy y y) ) ) or or or t t the he he m m mor or ore e e ad ad adva va vanc nc n ed ed d a a age ge ge o o of f controls.
Relationship between microvascular rarefaction and fibrosis in HFpEF
The inverse association of MVD with fibrosis in both control and HF patients suggests that microvascular rarefaction contributes to chronic ischemia and micro-scars 20, 49 and/or that a common process (such as microvascular endothelial inflammation) contributes to both microvascular rarefaction and myocardial fibrosis.
3, 18
Limitations
The use of autopsy specimens procured over a significant time span precludes detailed phenotypic characterization and cardiac function at the time of death is not known. Nonetheless, autopsy studies have been widely used to define the morphologic features of a variety of cardiovascular diseases. This study was limited to subjects who underwent autopsy, which is a small subset of the HFpEF population. Autopsy tissue banking does not include skeletal muscle precluding assessment of skeletal muscle MVD in our study. The number of HFrEF patients was small but the focus of this study was on HFpEF and the HFrEF group was included to provide an estimate of the relative severity of microvascular rarefaction and fibrosis in HFpEF and HFrEF.
Conclusions
This autopsy study describes the cardiac morphologic features of patients with an ante mortem diagnosis of HFpEF and age-appropriate controls. HFpEF patients had more severe cardiac hypertrophy, diffuse coronary disease, microvascular rarefaction and modesty more myocardial fibrosis than controls. Decreases in MVD were associated with greater fibrosis in both HFpEF .0001 % Area fibrosis 7.1 (5.1-9.0) 9.6 (6.8-13.5) <0.0001 % Ar Ar rea ea ea f f fib ib ibro ro osi si is s 7 7. 7 1 1 (5 (5 (5 1 .1 9 -9 9.0 0 0) ) ) 9 9. 9 6 6 6 (6 (6. 
